Cargando…

Esophageal cancer in the elderly: an analysis of the factors associated with treatment decisions and outcomes

BACKGROUND: Only limited data has been reported so far regarding oesophageal cancer (EC) in elderly patients. The aim of the study is to identify the baseline parameters that influenced therapeutic decision. METHODS: All consecutive patients 70 years or older being treated for EC were retrospectivel...

Descripción completa

Detalles Bibliográficos
Autores principales: Tougeron, David, Hamidou, Hadji, Scotté, Michel, Di Fiore, Frédéric, Antonietti, Michel, Paillot, Bernard, Michel, Pierre
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2010
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2955041/
https://www.ncbi.nlm.nih.gov/pubmed/20868479
http://dx.doi.org/10.1186/1471-2407-10-510
_version_ 1782188002869510144
author Tougeron, David
Hamidou, Hadji
Scotté, Michel
Di Fiore, Frédéric
Antonietti, Michel
Paillot, Bernard
Michel, Pierre
author_facet Tougeron, David
Hamidou, Hadji
Scotté, Michel
Di Fiore, Frédéric
Antonietti, Michel
Paillot, Bernard
Michel, Pierre
author_sort Tougeron, David
collection PubMed
description BACKGROUND: Only limited data has been reported so far regarding oesophageal cancer (EC) in elderly patients. The aim of the study is to identify the baseline parameters that influenced therapeutic decision. METHODS: All consecutive patients 70 years or older being treated for EC were retrospectively analyzed. Patients without visceral metastasis were divided into two groups: treatment with curative intent (chemoradiotherapy, surgery, radiotherapy, mucosectomy or photodynamic therapy) or best supportive care (BSC). Patients with metastasis were divided into two groups: palliative treatment (chemotherapy, chemoradiotherapy or radiotherapy) or BSC. RESULTS: Two hundred and eighty-two patients were studied. Mean age was 76.5 ± 5.5 years and 22.4% of patients had visceral metastasis. In patients without visceral metastasis (n = 220) the majority had treatment with curative intent (n = 151) whereas in patients with metastasis (n = 62) the majority had BSC (n = 32). Severe adverse events (≥ grade 3) were observed in only 17% of the patients. Patients without specific carcinologic treatment were older, had more weight loss, worse WHO performance status and Charlson score in multivariate analysis. DISCUSSION: Our results suggest that elderly patients with an EC could benefit from cancer treatment without major toxicities. Weight loss, WHO performance status and the Charlson score could be used to select the appropriate treatment in an elderly patient.
format Text
id pubmed-2955041
institution National Center for Biotechnology Information
language English
publishDate 2010
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-29550412010-10-15 Esophageal cancer in the elderly: an analysis of the factors associated with treatment decisions and outcomes Tougeron, David Hamidou, Hadji Scotté, Michel Di Fiore, Frédéric Antonietti, Michel Paillot, Bernard Michel, Pierre BMC Cancer Research Article BACKGROUND: Only limited data has been reported so far regarding oesophageal cancer (EC) in elderly patients. The aim of the study is to identify the baseline parameters that influenced therapeutic decision. METHODS: All consecutive patients 70 years or older being treated for EC were retrospectively analyzed. Patients without visceral metastasis were divided into two groups: treatment with curative intent (chemoradiotherapy, surgery, radiotherapy, mucosectomy or photodynamic therapy) or best supportive care (BSC). Patients with metastasis were divided into two groups: palliative treatment (chemotherapy, chemoradiotherapy or radiotherapy) or BSC. RESULTS: Two hundred and eighty-two patients were studied. Mean age was 76.5 ± 5.5 years and 22.4% of patients had visceral metastasis. In patients without visceral metastasis (n = 220) the majority had treatment with curative intent (n = 151) whereas in patients with metastasis (n = 62) the majority had BSC (n = 32). Severe adverse events (≥ grade 3) were observed in only 17% of the patients. Patients without specific carcinologic treatment were older, had more weight loss, worse WHO performance status and Charlson score in multivariate analysis. DISCUSSION: Our results suggest that elderly patients with an EC could benefit from cancer treatment without major toxicities. Weight loss, WHO performance status and the Charlson score could be used to select the appropriate treatment in an elderly patient. BioMed Central 2010-09-24 /pmc/articles/PMC2955041/ /pubmed/20868479 http://dx.doi.org/10.1186/1471-2407-10-510 Text en Copyright ©2010 Tougeron et al; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research Article
Tougeron, David
Hamidou, Hadji
Scotté, Michel
Di Fiore, Frédéric
Antonietti, Michel
Paillot, Bernard
Michel, Pierre
Esophageal cancer in the elderly: an analysis of the factors associated with treatment decisions and outcomes
title Esophageal cancer in the elderly: an analysis of the factors associated with treatment decisions and outcomes
title_full Esophageal cancer in the elderly: an analysis of the factors associated with treatment decisions and outcomes
title_fullStr Esophageal cancer in the elderly: an analysis of the factors associated with treatment decisions and outcomes
title_full_unstemmed Esophageal cancer in the elderly: an analysis of the factors associated with treatment decisions and outcomes
title_short Esophageal cancer in the elderly: an analysis of the factors associated with treatment decisions and outcomes
title_sort esophageal cancer in the elderly: an analysis of the factors associated with treatment decisions and outcomes
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2955041/
https://www.ncbi.nlm.nih.gov/pubmed/20868479
http://dx.doi.org/10.1186/1471-2407-10-510
work_keys_str_mv AT tougerondavid esophagealcancerintheelderlyananalysisofthefactorsassociatedwithtreatmentdecisionsandoutcomes
AT hamidouhadji esophagealcancerintheelderlyananalysisofthefactorsassociatedwithtreatmentdecisionsandoutcomes
AT scottemichel esophagealcancerintheelderlyananalysisofthefactorsassociatedwithtreatmentdecisionsandoutcomes
AT difiorefrederic esophagealcancerintheelderlyananalysisofthefactorsassociatedwithtreatmentdecisionsandoutcomes
AT antoniettimichel esophagealcancerintheelderlyananalysisofthefactorsassociatedwithtreatmentdecisionsandoutcomes
AT paillotbernard esophagealcancerintheelderlyananalysisofthefactorsassociatedwithtreatmentdecisionsandoutcomes
AT michelpierre esophagealcancerintheelderlyananalysisofthefactorsassociatedwithtreatmentdecisionsandoutcomes